Table 2 CMR features of the HCM patients depending on the presence and location of LGE on CMR
|  | HCM with I-LGE (Group 1, n = 22) | HCM with NI-LGE (Group 2, n = 36) | HCM without LGE (Group 3, n = 64) | ANOVA (P-value) | P 1 vs. 2 | P 1 vs. 3 | P 2 vs. 3 |
|---|---|---|---|---|---|---|---|
CMR findings | |||||||
 LVEF (%) | 69.14 (47.57, 73.58) | 69.45 (63.30, 78.93) | 70.92 (67.20, 79.04) | 0.032 | 0.304 | 0.026 | 0.987 |
 LVEDV (mL) | 130.60 (90.89, 151.90) | 117.10 (96.56, 129.50) | 112.50 (83.57, 131.70) | 0.167 | 0.991 | 0.193 |  > 0.999 |
 LVESV (mL) | 49.79 (28.90, 62.61) | 38.52 (19.20, 45.19) | 35.23 (19.68, 38.15) | 0.052 | 0.313 | 0.045 |  > 0.999 |
 LVSV (mL) | 75.33 ± 27.16 | 78.60 ± 19.36 | 77.24 ± 24.37 | 0.876 | 0.865 | 0.9424 | 0.958 |
 LV mass (g) | 170.8 (136.1, 202.6) | 128.50 (99.30, 164.3) | 111.6 (84.74, 129.5) |  < 0.001 | 0.122 |  < 0.001 | 0.024 |
 LV mass index (g/m2) | 1.41 ± 0.47 | 1.16 ± 0.27 | 1.01 ± 0.18 |  < 0.001 | 0.006 |  < 0.001 | 0.023 |
 Max LVWT (mm) | 19.50 (17.75, 25.00) | 18.67 (17.00, 20.00) | 16.77 (15.00, 18.00) |  < 0.001 | 0.415 |  < 0.001 | 0.003 |
 RVEF (%) | 64.30 (41.32, 69.33) | 60.39 (55.57, 68.29) | 58.32 (50.42, 68.05) | 0.608 |  > 0.999 |  > 0.999 | 0.966 |
 RVEDV (mL) | 99.07 (59.71, 131.7) | 95.29 (69.12, 115.2) | 97.33 (72.41, 114.8) | 0.712 |  > 0.999 |  > 0.999 |  > 0.999 |
 RVESV (mL) | 41.48 (28.53, 49.79) | 39.09 (26.05, 46.78) | 40.09 (27.26, 151.4) | 0.390 | 0.561 |  > 0.999 | 0.980 |
 RVSV (mL) | 25.09 ± 57.25 | 56.20 ± 21.48 | 57.24 ± 17.92 | 0.9678 | 0.980 |  > 0.999 | 0.967 |
 LVOT obstruction (n %) | 10 (45.45%) | 16 (19.88%) | 24 (54.54%) | 0.711 | - | - | - |
 LGE extent (%) | 13.77 ± 12.22 | 6.63 ± 3.60 | 0 |  < 0.001 | 0.267 |  < 0.001 |  < 0.001 |